Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II MAP ± denosumab regimen in metastatic osteosarcoma
2021-002366-41Phase 2Active
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in osteosarcoma (OS) (2 arms), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoint: Event-free survival at 5 years. Started Oct 2021; status: active.
02
Drugs
denosumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2021-002366-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002366-41.